“…As current clinical guidelines recommend combined therapy, usually including NRTI (Centers for Disease Control and Prevention, 1999), such regimens may be important to the development of mitochondrial toxicity in new tissue targets as treatment is prolonged because of the increased longevity of patients with AIDS. [The following references were cited only in Table 1: Barile et al, 1994Barile et al, , 1997Benbrik et al, 1997;Browne et al, 1993;Chen and Cheng, 1992;Cherrington et al, 1995;Corcuera et al, 1996;Cui et al, 1997;Dalakas et al, 1990;Elimadi et al, 1997. The following references were cited only in Table 1: Feldman and Anderson, 1994;Feldman et al, 1992;Hart et al, 1992;Hertzberg et al, 1992;Hobbs et al, 1992Hobbs et al, , 1995; Institute of Medicine (US) Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials, 1995;Izuta et al, 1991.…”